Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
FDA Orange Book
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Allo Uridine
2. Allo-uridine
3. Allouridine
1. 58-96-8
2. Uridin
3. Uracil Riboside
4. 1-beta-d-ribofuranosyluracil
5. Uracil, 1-beta-d-ribofuranosyl-
6. Beta-uridine
7. D-uridine
8. B-uridine
9. Nsc 20256
10. 1-.beta.-d-ribofuranosyluracil
11. Chebi:16704
12. Urd
13. Ai3-52690
14. 1-((2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidine-2,4(1h,3h)-dione
15. Whi7hq7h85
16. Mls000069625
17. Nsc-20256
18. Smr000058222
19. Mfcd00006526
20. 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione
21. 1-beta-d-ribofuranosylpyrimidine-2,4(1h,3h)-dione
22. 1-beta-d-ribofuranosylpyrimidine-2,4(1h,3h)-dione (uridine)
23. 1-((2r,3r,4s,5r)-tetrahydro-3,4-dihydroxy-5-(hydroxymethyl)furan-2-yl)pyrimidine-2,4(1h,3h)-dione
24. 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,3,4-tetrahydropyrimidine-2,4-dione
25. 3083-77-0
26. Einecs 200-407-5
27. Unii-whi7hq7h85
28. Arau
29. Nsc20256
30. D-ribosyl Uracil
31. .beta.-uridine
32. Uridine,(s)
33. 1af2
34. 4jx9
35. 4pd6
36. Opera_id_118
37. Uridine [inci]
38. Uridine, >=99%
39. Uridine [mi]
40. Uridine [mart.]
41. 1-b-d-ribofuranosyluracil
42. Uridine [usp-rs]
43. Uridine [who-dd]
44. 1-a-d-ribofuranosyluracil
45. Bmse000158
46. Bmse000816
47. Bmse000864
48. Epitope Id:149164
49. 1-.beta.-d-ribofuranosyl-2,4(1h,3h)-pyrimidinedione
50. Beta-d-ribofuranosyl-uridine
51. Schembl20667
52. Uracil-1-a-d-ribofuranoside
53. Rg2417
54. Uridine, Bioultra, >=99%
55. Uridine [usp Impurity]
56. Chembl100259
57. Gtpl4566
58. 1-beta-delta-ribofuranosyluracil
59. Dtxsid40891555
60. Uracil-1-.beta.-d-ribofuranoside
61. Hms2230p13
62. Hms3884m20
63. Hy-b1449
64. Zinc2583633
65. Bdbm50088517
66. S2029
67. Akos015896922
68. Am83934
69. Ccg-214447
70. Cs-5153
71. Db02745
72. Smp1_000029
73. Ncgc00017312-02
74. Ncgc00017312-04
75. Ncgc00017312-05
76. Ncgc00142368-01
77. 1-[(4s,2r,3r,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3-dihydropyrimi Dine-2,4-dione
78. Ds-14345
79. Sri-10895_12
80. Uridine, Vetec(tm) Reagent Grade, 99%
81. Adenosine Impurity F [ep Impurity]
82. Db-030519
83. U0020
84. C00299
85. 1-b-d-ribofuranosyl-2,4(1h,3h)-pyrimidinedione
86. B-d-ribofuranoside 2,4(1h,3h)-pyrimidinedione-1
87. Q422573
88. Brd-k13050303-001-18-1
89. Uridine, Powder, Bioreagent, Suitable For Cell Culture
90. .beta.-d-ribofuranoside, 2,4(1h,3h)-pyrimidinedione-1
91. 1-beta-delta-ribofuranosyl-2,4(1h,3h)-pyrimidinedione
92. 6b6fa3f8-70a2-44ea-b99c-d35d0a9237aa
93. Beta-delta-ribofuranoside 2,4(1h,3h)-pyrimidinedione-1
94. 1-.beta.-d-ribofuranosylpyrimidine-2,4(1h,3h)-dione
95. 1-beta-d-ribofuranosyluracil, Uracil-1-beta-d-ribofuranoside
96. Uridine, United States Pharmacopeia (usp) Reference Standard
97. 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidine-2,4-dione
98. Uridine, Pharmagrade, Manufactured Under Appropriate Controls For Use As A Raw Material In Pharma Or Biopharmaceutical Production
Molecular Weight | 244.20 g/mol |
---|---|
Molecular Formula | C9H12N2O6 |
XLogP3 | -2 |
Hydrogen Bond Donor Count | 4 |
Hydrogen Bond Acceptor Count | 6 |
Rotatable Bond Count | 2 |
Exact Mass | 244.06953611 g/mol |
Monoisotopic Mass | 244.06953611 g/mol |
Topological Polar Surface Area | 119 Ų |
Heavy Atom Count | 17 |
Formal Charge | 0 |
Complexity | 371 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 4 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Investigated for use/treatment in bipolar disorders and manic disorders.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 4568
Submission : 1982-04-23
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 23211
Submission : 2009-10-10
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 3349
Submission : 1978-10-24
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 5272
Submission : 1984-03-02
Status : Inactive
Type : II
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Global Sales Information
POLIFARMA SpA
Dosage Form :
Dosage Strength : 20 Cpr 100 Mg + 100 Mg
Price Per Pack (Euro) : 8.21
Published in :
Country : Italy
RX/OTC/DISCN : Class C
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
POLIFARMA SpA
Dosage Form :
Dosage Strength : Os Soluz 10 Vials 150 Mg + 150 Mg 10 Ml
Price Per Pack (Euro) : 8.21
Published in :
Country : Italy
RX/OTC/DISCN : Class C
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
POLIFARMA SpA
Dosage Form :
Dosage Strength : 5 Ampoules Im Ev 150 Mg + 150Mg + 5 Vials ...
Price Per Pack (Euro) : 10.95
Published in :
Country : Italy
RX/OTC/DISCN : Class C
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Market Place
Reply
18 Dec 2019
Reply
24 Jul 2018
Reply
22 Jun 2017
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?